Appendix B. Sources of evidence considered by the Committee
A. The following manufacturer/sponsor provided a submission for this appraisal:
Eli Lilly & Company Ltd
B. The evidence review group (ERG) report for this appraisal was prepared by Southampton Health Technology Assessment Centre:J Jones, A Takeda, SC Tan, K Cooper, E Loveman, A Clegg, N Murray (July 2006). Gemcitabine for metastatic breast cancer.
C. The following individuals were selected from clinical specialist and patient advocate nominations from the professional/specialist and patient/carer groups. They gave their expert personal views on gemcitabine plus paclitaxel by providing written and/or oral evidence to the Committee. They were also invited to comment on the Appraisal Consultation Document (ACD).
Professor Steve Heys, Professor of Surgical Oncology, nominated by the British Association of Surgical Oncologists as a clinical specialist
Dr Andreas Makris, Consultant Clinical Oncologist, nominated by the Royal College of Physicians as a clinical specialist
Dr Mark Verrill, Consultant Medical Oncologist, nominated by the Royal College of Physicians as a clinical specialist
Maria Leadbeater, Nurse Specialist Secondary Breast Cancer, nominated by Breast Cancer Care as a patient expert
Anna Wood, Policy and Campaigns Manager, nominated by Breast Cancer Care as a patient expert.